{"id":"rimegepant-bhv3000","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)","action":"Monitor","effect":"Increased rimegepant exposure"},{"drug":"P-glycoprotein inducers (e.g., rifampin, St. John's Wort)","action":"Monitor","effect":"Decreased rimegepant exposure"},{"drug":"Strong CYP3A inhibitors (e.g., itraconazole, clarithromycin)","action":"Monitor","effect":"Increased rimegepant exposure"},{"drug":"Strong CYP3A inducers (e.g., rifampin, St. John's Wort)","action":"Monitor","effect":"Decreased rimegepant exposure"},{"drug":"CYP3A substrates (e.g., midazolam, triazolam)","action":"Monitor","effect":"Increased exposure to CYP3A substrates"},{"drug":"CYP2C19 substrates (e.g., omeprazole, lansoprazole)","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"}],"commonSideEffects":[],"contraindications":["Patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or to any of its components.","Do not take NURTEC ODT if you are: • allergic to rimegepant, NURTEC ODT, or any of the ingredients "],"specialPopulations":{"Pregnancy":"Use should be avoided. AU TGA pregnancy category: B1US FDA pregnancy category: Not assigned. Risk summary: Inadequate data available on the use of this drug in pregnant women to inform a drug-related risk. Comments: -A pregnancy exposure registry is available. Animal studies have revealed evidence of embryofetal toxicity and teratogenicity.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=rimegepant-bhv3000","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:36:04.136883+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:36:09.839331+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:36:04.204578+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rimegepant-bhv3000","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:36:10.288228+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Calcitonin gene-related peptide type 1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:36:11.442368+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2364629/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:36:11.109695+00:00"}},"allNames":"rimegepant/bhv3000","offLabel":[],"timeline":[],"aiSummary":"Rimegepant/BHV3000 is a marketed drug by Pfizer Inc. for the acute treatment of migraine with or without aura in adults and prevention of migraine in adults. It has 17 trials but no publications. The commercial significance and pipeline developments are not specified. Rimegepant/BHV3000 is a small molecule drug. It is used for its pharmacological class and modality. The novelty of the drug is not specified.","brandName":"Rimegepant/BHV3000","ecosystem":[],"isGeneric":true,"mechanism":{"target":"calcitonin gene-related peptide receptor (CGRPR)","novelty":"novelty not specified","modality":"small molecule","drugClass":"pharmacological class not specified","explanation":"","oneSentence":"","technicalDetail":"Rimegepant/BHV3000 is a small molecule drug that targets the calcitonin gene-related peptide receptor (CGRPR). It works by binding to the CGRPR and inhibiting the release of calcitonin gene-related peptide (CGRP), which is a key player in migraine pathophysiology."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$79,491.09","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=rimegepant-bhv3000","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rimegepant-bhv3000","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:36:12.873740+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Ubrelvy (ubrogepant)","company":"prescription medicine","advantage":"works by blocking the effects of a protein, called CGRP that is thought to play a role in migraine"},{"name":"Sumatriptan","company":"n/a","advantage":"n/a"},{"name":"Nurtec ODT","company":"n/a","advantage":"n/a"},{"name":"Imitrex","company":"n/a","advantage":"n/a"},{"name":"Rizatriptan","company":"n/a","advantage":"n/a"},{"name":"Botox","company":"n/a","advantage":"n/a"},{"name":"Topiramate","company":"anticonvulsant","advantage":"used to treat partial-onset and tonic-clonic seizures and Lennox-Gastaut syndrome in adults and children aged 2 and older, and to prevent migraines in those aged 12"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"rimegepant-bhv3000","indications":{"approved":[{"name":"Acute treatment of migraine with or without aura in adults","regulator":"FDA"},{"name":"Prevention of migraine in adults","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05156398","phase":"PHASE3","title":"Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-02-28","conditions":"Migraine","enrollment":640},{"nctId":"NCT04649242","phase":"PHASE3","title":"Randomized Study in Children and Adolescents With Migraine: Acute Treatment","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-01-15","conditions":"Pediatric Migraine","enrollment":2100},{"nctId":"NCT05810038","phase":"PHASE3","title":"A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-15","conditions":"Migraine","enrollment":787},{"nctId":"NCT05399485","phase":"PHASE3","title":"Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-09","conditions":"Migraine","enrollment":496},{"nctId":"NCT05207865","phase":"PHASE4","title":"Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-15","conditions":"Migraine, Episodic Migraine, Phonophobia","enrollment":441},{"nctId":"NCT05248997","phase":"PHASE3","title":"Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-02-17","conditions":"Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps","enrollment":261},{"nctId":"NCT05399459","phase":"PHASE3","title":"Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-09","conditions":"Migraine","enrollment":897},{"nctId":"NCT05371652","phase":"PHASE3","title":"A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-05-19","conditions":"Acute Migraine","enrollment":241},{"nctId":"NCT03941834","phase":"PHASE2","title":"Trial for Treatment Refractory Trigeminal Neuralgia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-06-25","conditions":"Trigeminal Neuralgia","enrollment":65},{"nctId":"NCT03732638","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-14","conditions":"Migraine","enrollment":1590},{"nctId":"NCT05262517","phase":"PHASE3","title":"Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-05-05","conditions":"Temporomandibular Disorders (TMD)","enrollment":126},{"nctId":"NCT04574362","phase":"PHASE3","title":"Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-10-22","conditions":"Acute Migraine","enrollment":1648},{"nctId":"NCT03934086","phase":"","title":"An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine","status":"NO_LONGER_AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"Migraine","enrollment":""},{"nctId":"NCT03461757","phase":"PHASE3","title":"Trial in Adult Subjects With Acute Migraines","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-02-27","conditions":"Migraine, With or Without Aura","enrollment":1811},{"nctId":"NCT03237845","phase":"PHASE3","title":"Safety and Efficacy in Adult Subjects With Acute Migraines","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-27","conditions":"Migraine, With or Without Aura","enrollment":1499},{"nctId":"NCT03266588","phase":"PHASE2, PHASE3","title":"Open Label Safety Study in Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-08-30","conditions":"Migraine, With or Without Aura","enrollment":3019},{"nctId":"NCT03235479","phase":"PHASE3","title":"Safety and Efficacy Study in Adult Subjects With Acute Migraines","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-18","conditions":"Migraine, With or Without Aura","enrollment":1485}],"_emaApprovals":[{"date":"","name":"Rimegepant/BHV3000","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.persistencemarketresearch.com/market-research/cgrp-inhibitors-market.asp","date":"2026-04-07","type":"news","title":"CGRP Inhibitors Market Size, Industry Share & Trends, 2033","source":"www.persistencemarketresearch.com"},{"url":"https://www.sec.gov/Archives/edgar/data/1689813/000168981321000090/bhvn-20210331.htm","date":"2026-04-07","type":"news","title":"bhvn-20210331 - SEC.gov","source":"www.sec.gov"},{"url":"https://en.wikipedia.org/wiki/Rimegepant","date":"2026-04-07","type":"news","title":"Rimegepant - Wikipedia","source":"en.wikipedia.org"},{"url":"https://cdn.clinicaltrials.gov/large-docs/65/NCT05207865/Prot_000.pdf","date":"2026-04-07","type":"news","title":"BHV-3000 (PF-07899801) (rimegepant) STUDY NUMBER(S)","source":"cdn.clinicaltrials.gov"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/biohaven-and-pfizer-announce-positive-top-line-results","date":"2026-04-07","type":"news","title":"Biohaven and Pfizer Announce Positive Top-Line Results ...","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL2364629","moleculeType":"Small molecule","molecularWeight":"1221.26"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2364629"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"commercialAnalysis":{"text":"Rimegepant/BHV3000, developed by Pfizer, is a small molecule CGRP antagonist used for the acute treatment of migraine with or without aura in adults and prevention of migraine in adults. As of 2026, the global CGRP inhibitors market size is expected to be valued at US$ 6.5 billion, growing at a CAGR of 9.7% between 2026 and 2033 [1]. Rimegepant/BHV3000 is likely to contribute to this growth, although specific revenue figures for the drug are not provided.\n\nThe competitive landscape for CGRP inhibitors is dominated by monoclonal antibody therapies such as erenumab, fremanezumab, and galcanezumab [1]. These treatments have reshaped migraine management by providing more precise mechanisms of action and improved tolerability. However, high therapy costs and reimbursement restrictions pose a threat to the market's growth [1]. Rimegepant/BHV3000's competitive position is uncertain, as it is a small molecule CGRP antagonist, which may have different pharmacokinetic and pharmacodynamic profiles compared to monoclonal antibodies.\n\nKey upcoming catalysts for the CGRP inhibitors market include patent cliffs, label expansions, and pipeline competitors. As the market continues to expand, manufacturers are exploring new delivery formats and next-generation CGRP agents [1]. Additionally, clinical research into broader patient populations and combination therapies may lead to new indications and revenue streams for Rimegepant/BHV3000.\n\nThe market outlook for Rimegepant/BHV3000 is uncertain, as it depends on various factors such as market share, pricing, and reimbursement. However, the growing demand for effective migraine treatments and the expanding CGRP inhibitors market suggest a promising future for Rimegepant/BHV3000. Further research and data are needed to determine the drug's specific market position and revenue trajectory.\n\nReferences:\n[1] Persistencemarketresearch.com, CGRP Inhibitors Market Size, Industry Share & Trends, 2033, February 2026.","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.persistencemarketresearch.com/market-research/cgrp-inhibitors-market.asp","date":"","title":"CGRP Inhibitors Market Size, Industry Share & Trends, 2033","source":"www.persistencemarketresearch.com"},{"url":"https://www.sec.gov/Archives/edgar/data/1689813/000168981321000090/bhvn-20210331.htm","date":"","title":"bhvn-20210331 - SEC.gov","source":"www.sec.gov"},{"url":"https://en.wikipedia.org/wiki/Rimegepant","date":"","title":"Rimegepant - Wikipedia","source":"en.wikipedia.org"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"79491.09","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:36:12.873740+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}